Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31078956 | 0.81 | DPP4 (0.46) | ALDH1A1MAPTPTGS1DPP4OPRM1 | |
| SCHEMBL31674469 | 0.81 | ALDH1A1 (0.57) | ALDH1A1MAPTPTGS1DPP4 | |
| SCHEMBL29666118 | 0.80 | PTGS1 (0.45) | ALDH1A1MAPTPTGS1OPRM1 | |
| SCHEMBL31344450 | 0.80 | ALDH1A1 (0.42) | ALDH1A1MAPTPTGS1DPP4OPRM1 | |
| SCHEMBL31413983 | 0.80 | ALDH1A1 (0.42) | ALDH1A1MAPTPTGS1DPP4OPRM1 | |
| SCHEMBL29378289 | 0.80 | PTGS1 (0.42) | ALDH1A1MAPTPTGS1DPP4OPRM1 | |
| SCHEMBL31237035 | 0.80 | ALDH1A1 (0.42) | ALDH1A1MAPTPTGS1DPP4OPRM1 | |
| SCHEMBL29157274 | 0.80 | ALDH1A1 (0.40) | ALDH1A1MAPTPTGS1OPRM1 | |
| SCHEMBL29157272 | 0.80 | ALDH1A1 (0.40) | ALDH1A1MAPTPTGS1OPRM1 | |
| SCHEMBL3491102 | 0.79 | ALDH1A1 (0.41) | ALDH1A1MAPTPTGS1DPP4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | claimed |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | claimed |
| EP-4658374-A1 | METHODS FOR PREPARING CRYSTALLINE PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | claimed |
| EP-4613761-A9 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | claimed |
| EP-4613761-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4090670-B1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2025-06-04 | — | — | EP | claimed |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-11-21 | — | — | US | claimed |
| WO-2024163643-A1 | METHODS FOR PREPARING CRYSTALLINE PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-08 | — | — | WO | claimed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | claimed |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | claimed |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. | 2022-12-22 | — | — | US | claimed |
| EP-4090670-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| EP-4090669-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| CN-115298196-A | Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-04 | — | — | CN | claimed |
| CN-115279782-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-01 | — | — | CN | claimed |
| US-20220177532-A1 | COMPOSITIONS OF PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | PROTAGONIST THERAPEUTICS, INC. | 2022-06-09 | — | — | US | claimed |
| WO-2022109328-A1 | COMPOSITIONS OF PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-27 | — | — | WO | claimed |
| EP-3997105-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Protagonist Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| CN-114341161-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 领导医疗有限公司 | 2022-04-12 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | ALDH1A1 4766/4885MAPT 4562/4885PTGS1 2216/4885 |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | ALDH1A1 4574/4885MAPT 2759/4885PTGS1 908/4885 |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL17A, IL36G | ALDH1A1 4702/4885MAPT 843/4885PTGS1 1571/4885 |
| US-20220177532-A1 | COMPOSITIONS OF PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL17A | ALDH1A1 4696/4885MAPT 1523/4885PTGS1 1233/4885 |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | ALDH1A1 4574/4885MAPT 2759/4885PTGS1 908/4885 |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | ALDH1A1 4574/4885MAPT 2759/4885PTGS1 908/4885 |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, IL36G | ALDH1A1 3940/4885MAPT 3697/4885PTGS1 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.